Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dazukibart Phase 2 in Dermatomyositis
NCT03181893Phase 2Completed
- Sponsor
- Pfizer
- Start
- Jan 2018
- Primary completion
- May 2022
- Modality
- Monoclonal Antibodies
- Countries
- 5
01
Overview
A Phase 2 trial of dazukibart in dermatomyositis (DM), sponsored by Pfizer. Started Jan 2018; status: completed.
02
Drugs
dazukibart
03
Conditions
dermatomyositis (DM)
Beyond the preview
Go deeper on NCT03181893.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03181893.